INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. (URGN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, all dates inclusive (the 'Class Period'), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen as well as certain of UroGen's top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-urogen-pharma-ltd-class-action-lawsuit-urgn.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].
CASE ALLEGATIONS: UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.
The UroGen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved.
The UroGen class action lawsuit further alleges that on May 16, 2025, the FDA published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's NDA for UGN-102, which stated that '[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret,' and that the FDA had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock fell nearly 26%, according to the complaint.
Then, on May 21, 2025, the UroGen class action lawsuit further alleges that the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk of the investigation therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock fell nearly 45%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UroGen securities during the Class Period to seek appointment as lead plaintiff in the UroGen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UroGen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UroGen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UroGen class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
8 minutes ago
- Wall Street Journal
Voyager Technologies Rises in Debut, Signaling Improving IPO Market
Shares of space and defense technology company Voyager Technologies surged in their New York Stock Exchange debut Wednesday, another sign of an improving market for initial public offerings. The stock ended the regular session at $56.48 and was up 6% after hours to $60.15.
Skift
9 minutes ago
- Skift
Planners Fear Immigration Crackdowns Will Make Hotel Labor Shortages Worse: Exclusive Survey
The hospitality industry has struggled with a labor shortage since the Covid pandemic. Now, immigration enforcement and an anti-immigrant sentiment are adding a new layer of complexity. An exclusive Skift Meetings survey of U.S. planners shows that they expect to grapple with the effects of Trump-era immigration policies on their events, with growing concern about hotel staffing across the board. More than two-thirds of respondents (72%) said they expect hotel staffing to be affected in 2025–2026 because of immigration policies. Only 13% foresaw no impact. 'Hotel staffing never fully bounced back after the pandemic. We're still experiencing some gaps in service in certain markets and at certain properties,' said Kyle Jordan, director of meetings at the Institute for Operations Research and Management Sciences (INFORMS). Staffing issues are being felt at more than hotels. 'Challenges extend to other key partners like AV providers and vendors that support our meetings,' said Jordan. 'While it's hard to predict the full impact, I would expect that deportation activity could further strain staffing in some destinations.' Concerns stem not just from general staffing shortages but also the effect of revived immigration enforcement policies. 'The main issue is that for many workers in hotels, while they may be legal immigrants, the feeling toward immigrants in general has turned toxic,' said Mark Phillips, CEO of LamontCo. 'No one wants to live and work in such an environment or put families through it, so over time we will see less available even legal immigrant workforces. It already appears to be happening in several cities.' ICE Raids and Protests Exacerbate Immigration Issues In Los Angeles, several days of protests followed large-scale immigration raids by ICE. Protests have spread to other U.S. cities, including Atlanta, Chicago, Washington, D.C, and New York City. a'The hospitality industry relies heavily on immigrant labor especially in back-of-house roles like housekeeping, food and beverage service, and maintenance. Stricter immigration enforcement, increased deportations, and general anti-immigration rhetoric have created fear and uncertainty among these workers, not to mention ICE raids, and I-9 audits. This leads some to leave the industry or self-deport, reducing the labor pool, making it even harder for hotels to fill critical positions,' said Robert Kraus, founder of Small Conferences. Kraus added that there are concerns about the future of the H-2B visa program and similar initiatives. 'There's also a worry that H-2B visas and other temporary worker programs will be curtailed plus general apprehension on potential workers to risk coming to the U.S. just to be told they can't enter or later be sent home only after a short amount of time. This could easily limit the number of foreign workers applying, which is critical for meeting seasonal demands of resorts and other hospitality businesses.' Labor shortages have already disrupted event logistics.'In several cases, my groups suffered through multi-hour lunch services because the hotel restaurant kitchen could not keep up with demand,' he said. Legal Compliance Doesn't Eliminate Anxiety Michael Dominguez, president and CEO of ALHI, argues that deportation is not necessarily a direct impact to hotel staffing. 'It has been required by law for any employee to complete an I-9 form, which verifies legal status and requires documentation,' said Dominguez. 'Any company or hotel not doing that is in violation of Section 274A of the Immigration and Nationality Act of 1986. Everyone working in a hotel needs documentation, or they are breaking the law.' Still, legal status does not erase worker anxiety, said Melanie Nathan, human rights advocate and executive director of the African Human Rights Coalition. 'I know people who are perfectly legal and who have filled in those I-9's who are too scared to go to work. They are standing back to try and ride out what they feel like is a storm. Some fear they might get picked up in workplaces where there are likely to be raids.' Guest Services and Sales Take a Hit The staffing crunch is also affecting guest experience and hotel revenue. 'Daily housekeeping is no longer a given. There are hotels where it is now every other day or on request,' said Akshar Patel, VP of corporate strategy and development at eShow Event Management Solutions and a hospitality expert. Beyond guest services, the staffing crunch is slowing business development efforts. 'A staffing shortage on the sales side is delaying RFPs,' said Patel. Andrea Milrad Heilweil, VP of sales and marketing at The Hutton Group, agrees. 'I have found that since Covid I have to be much more proactive with follow-up. Between people furloughed, laid off, or leaving the industry altogether, RFP responses, requests for contracts, setting up site visits, and general communication have been delayed.'
CBS News
9 minutes ago
- CBS News
Dr. Macquline King named interim Chicago Public Schools CEO by Board of Education
The Chicago Board of Education selected City Hall employee Dr. Macquline King to be the interim CEO of Chicago Public Schools. The board voted on her appointment Wednesday. King will replace outgoing CPS CEO Pedro Martinez, who the board voted out in December 2024 amid an ongoing battle with Mayor Brandon Johnson over funding for the city's public school system. In September 2024, Martinez said he refused a request from Johnson to resign from his post after he declined the mayor's request to take out a $300 million high-interest short-term loan to pay for the costs of the proposed new Chicago teachers' contract and pension costs previously covered by the city. The entire previous school board resigned in October after being pressured by the mayor to fire Martinez. Johnson chose a new school board within days. In November, 10 new members of the school board were elected by the people of Chicago. CPS has been searching for a new permanent head for the district ever since, and a new permanent head has yet to be selected. So far, Dr. King is only the interim CPS CEO. She currently serves as the senior director of educational policy at City Hall. CPS faces a deficit of over half a billion dollars for the 2026 fiscal year, which begins July 1.
